Osaic Holdings
CYTO

Osaic Holdings’s Altamira Therapeutics Ltd CYTO Stock Holding History

Osaic Holdings’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$19 – 7633
2023
Q1 		$19 Hold
1
– – ﹤0.01% 7430
2022
Q4 		$0 Hold
1
– – ﹤0.01% 7560
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7622
2022
Q2 		$0 Buy
+1
New +$323 ﹤0.01% 7707
2022
Q1 		– Sell
-1
Closed -$483 – 7651
2021
Q4 		$1K Sell
1
-4
-80% -$2.68K ﹤0.01% 7296
2021
Q3 		$4K Sell
5
-11
-69% -$12.4K ﹤0.01% 6679
2021
Q2 		$23K Buy
16
+4
+33% +$5.49K ﹤0.01% 5588
2021
Q1 		$16K Buy
12
+2
+20% +$2.68K ﹤0.01% 5635
2020
Q4 		$11K Buy
10
+4
+67% +$2.57K ﹤0.01% 5493
2020
Q3 		$2K Buy
+6
New +$2.26K ﹤0.01% 5919

Other funds holding CYTO

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SCA
Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Osaic Holdings's CYTO Position: Q2 2023 in Review

Osaic Holdings sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2023, closing a stake of 1 share — an estimated $19 sold.

Osaic Holdings first reported a position in CYTO in Q3 2020 and held it in 10 quarters. The position peaked at $23K in Q2 2021. 5 funds tracked by Wall St. Rank hold CYTO as of Q2 2023.

  • Osaic Holdings reported no remaining Altamira Therapeutics Ltd position as of Q2 2023 after selling out during the quarter.
  • Osaic Holdings sold 1 Altamira Therapeutics Ltd share in Q2 2023, an estimated $19.
  • Osaic Holdings first reported a position in Altamira Therapeutics Ltd in Q3 2020 and held it in 10 quarters.
  • Osaic Holdings's Altamira Therapeutics Ltd position peaked at $23K in Q2 2021.
  • 5 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2023.

Based on Osaic Holdings's 13F filing for Q2 2023, filed 10 Aug 2023.